Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Gyöngyösi, M, Pokushalov, E, Romanov, A, Perin, E, Hare, JM, Kastrup, J, Fernández-Avilés, F, Sanz-Ruiz, R, Mathur, A, Wojakowski, W, Martin-Rendon, E, Pavo, N, Pavo, IJ, Hemetsberger, R, Traxler, D, Spannbauer, A & Haller, PM 2022, 'Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data', Journal of Clinical Medicine, vol. 11, no. 11, 3205. https://doi.org/10.3390/jcm11113205

APA

Gyöngyösi, M., Pokushalov, E., Romanov, A., Perin, E., Hare, J. M., Kastrup, J., Fernández-Avilés, F., Sanz-Ruiz, R., Mathur, A., Wojakowski, W., Martin-Rendon, E., Pavo, N., Pavo, I. J., Hemetsberger, R., Traxler, D., Spannbauer, A., & Haller, P. M. (2022). Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. Journal of Clinical Medicine, 11(11), [3205]. https://doi.org/10.3390/jcm11113205

CBE

Gyöngyösi M, Pokushalov E, Romanov A, Perin E, Hare JM, Kastrup J, Fernández-Avilés F, Sanz-Ruiz R, Mathur A, Wojakowski W, Martin-Rendon E, Pavo N, Pavo IJ, Hemetsberger R, Traxler D, Spannbauer A, Haller PM. 2022. Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. Journal of Clinical Medicine. 11(11):Article 3205. https://doi.org/10.3390/jcm11113205

MLA

Vancouver

Author

Gyöngyösi, Mariann ; Pokushalov, Evgeny ; Romanov, Aleksander ; Perin, Emerson ; Hare, Joshua M ; Kastrup, Jens ; Fernández-Avilés, Francisco ; Sanz-Ruiz, Ricardo ; Mathur, Anthony ; Wojakowski, Wojcieh ; Martin-Rendon, Enca ; Pavo, Noemi ; Pavo, Imre J ; Hemetsberger, Rayyan ; Traxler, Denise ; Spannbauer, Andreas ; Haller, Paul M. / Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. In: Journal of Clinical Medicine. 2022 ; Vol. 11, No. 11.

Bibtex

@article{044a071d83344154b6fe9ad240f74551,
title = "Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data",
abstract = "Individual patient data (IPD)-based meta-analysis (ACCRUE, meta-analysis of cell-based cardiac studies, NCT01098591) revealed an insufficient effect of intracoronary cell-based therapy in acute myocardial infarction. Patients with ischemic heart failure (iHF) have been treated with reparative cells using percutaneous endocardial, surgical, transvenous or intracoronary cell delivery methods, with variable effects in small randomized or cohort studies. The objective of this meta-analysis was to investigate the safety and efficacy of percutaneous transendocardial cell therapy in patients with iHF. Two investigators extracted the data. Individual patient data (IPD) (n = 8 studies) and publication-based (n = 10 studies) aggregate data were combined for the meta-analysis, including patients (n = 1715) with chronic iHF. The data are reported in accordance with PRISMA guidelines. The primary safety and efficacy endpoints were all-cause mortality and changes in global ejection fraction. The secondary safety and efficacy endpoints were major adverse events, hospitalization and changes in end-diastolic and end-systolic volumes. Post hoc analyses were performed using the IPD of eight studies to find predictive factors for treatment safety and efficacy. Cell therapy was significantly (p < 0.001) in favor of survival, major adverse events and hospitalization during follow-up. A forest plot analysis showed that cell therapy presents a significant benefit of increasing ejection fraction with a mean change of 2.51% (95% CI: 0.48; 4.54) between groups and of significantly decreasing end-systolic volume. The analysis of IPD data showed an improvement in the NYHA and CCS classes. Cell therapy significantly decreased the end-systolic volume in male patients; in patients with diabetes mellitus, hypertension or hyperlipidemia; and in those with previous myocardial infarction and baseline ejection fraction ≤ 45%. The catheter-based transendocardial delivery of regenerative cells proved to be safe and effective for improving mortality and cardiac performance. The greatest benefit was observed in male patients with significant atherosclerotic co-morbidities.",
author = "Mariann Gy{\"o}ngy{\"o}si and Evgeny Pokushalov and Aleksander Romanov and Emerson Perin and Hare, {Joshua M} and Jens Kastrup and Francisco Fern{\'a}ndez-Avil{\'e}s and Ricardo Sanz-Ruiz and Anthony Mathur and Wojcieh Wojakowski and Enca Martin-Rendon and Noemi Pavo and Pavo, {Imre J} and Rayyan Hemetsberger and Denise Traxler and Andreas Spannbauer and Haller, {Paul M}",
year = "2022",
month = jun,
day = "4",
doi = "10.3390/jcm11113205",
language = "English",
volume = "11",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "11",

}

RIS

TY - JOUR

T1 - Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data

AU - Gyöngyösi, Mariann

AU - Pokushalov, Evgeny

AU - Romanov, Aleksander

AU - Perin, Emerson

AU - Hare, Joshua M

AU - Kastrup, Jens

AU - Fernández-Avilés, Francisco

AU - Sanz-Ruiz, Ricardo

AU - Mathur, Anthony

AU - Wojakowski, Wojcieh

AU - Martin-Rendon, Enca

AU - Pavo, Noemi

AU - Pavo, Imre J

AU - Hemetsberger, Rayyan

AU - Traxler, Denise

AU - Spannbauer, Andreas

AU - Haller, Paul M

PY - 2022/6/4

Y1 - 2022/6/4

N2 - Individual patient data (IPD)-based meta-analysis (ACCRUE, meta-analysis of cell-based cardiac studies, NCT01098591) revealed an insufficient effect of intracoronary cell-based therapy in acute myocardial infarction. Patients with ischemic heart failure (iHF) have been treated with reparative cells using percutaneous endocardial, surgical, transvenous or intracoronary cell delivery methods, with variable effects in small randomized or cohort studies. The objective of this meta-analysis was to investigate the safety and efficacy of percutaneous transendocardial cell therapy in patients with iHF. Two investigators extracted the data. Individual patient data (IPD) (n = 8 studies) and publication-based (n = 10 studies) aggregate data were combined for the meta-analysis, including patients (n = 1715) with chronic iHF. The data are reported in accordance with PRISMA guidelines. The primary safety and efficacy endpoints were all-cause mortality and changes in global ejection fraction. The secondary safety and efficacy endpoints were major adverse events, hospitalization and changes in end-diastolic and end-systolic volumes. Post hoc analyses were performed using the IPD of eight studies to find predictive factors for treatment safety and efficacy. Cell therapy was significantly (p < 0.001) in favor of survival, major adverse events and hospitalization during follow-up. A forest plot analysis showed that cell therapy presents a significant benefit of increasing ejection fraction with a mean change of 2.51% (95% CI: 0.48; 4.54) between groups and of significantly decreasing end-systolic volume. The analysis of IPD data showed an improvement in the NYHA and CCS classes. Cell therapy significantly decreased the end-systolic volume in male patients; in patients with diabetes mellitus, hypertension or hyperlipidemia; and in those with previous myocardial infarction and baseline ejection fraction ≤ 45%. The catheter-based transendocardial delivery of regenerative cells proved to be safe and effective for improving mortality and cardiac performance. The greatest benefit was observed in male patients with significant atherosclerotic co-morbidities.

AB - Individual patient data (IPD)-based meta-analysis (ACCRUE, meta-analysis of cell-based cardiac studies, NCT01098591) revealed an insufficient effect of intracoronary cell-based therapy in acute myocardial infarction. Patients with ischemic heart failure (iHF) have been treated with reparative cells using percutaneous endocardial, surgical, transvenous or intracoronary cell delivery methods, with variable effects in small randomized or cohort studies. The objective of this meta-analysis was to investigate the safety and efficacy of percutaneous transendocardial cell therapy in patients with iHF. Two investigators extracted the data. Individual patient data (IPD) (n = 8 studies) and publication-based (n = 10 studies) aggregate data were combined for the meta-analysis, including patients (n = 1715) with chronic iHF. The data are reported in accordance with PRISMA guidelines. The primary safety and efficacy endpoints were all-cause mortality and changes in global ejection fraction. The secondary safety and efficacy endpoints were major adverse events, hospitalization and changes in end-diastolic and end-systolic volumes. Post hoc analyses were performed using the IPD of eight studies to find predictive factors for treatment safety and efficacy. Cell therapy was significantly (p < 0.001) in favor of survival, major adverse events and hospitalization during follow-up. A forest plot analysis showed that cell therapy presents a significant benefit of increasing ejection fraction with a mean change of 2.51% (95% CI: 0.48; 4.54) between groups and of significantly decreasing end-systolic volume. The analysis of IPD data showed an improvement in the NYHA and CCS classes. Cell therapy significantly decreased the end-systolic volume in male patients; in patients with diabetes mellitus, hypertension or hyperlipidemia; and in those with previous myocardial infarction and baseline ejection fraction ≤ 45%. The catheter-based transendocardial delivery of regenerative cells proved to be safe and effective for improving mortality and cardiac performance. The greatest benefit was observed in male patients with significant atherosclerotic co-morbidities.

UR - http://www.scopus.com/inward/record.url?scp=85131206575&partnerID=8YFLogxK

U2 - 10.3390/jcm11113205

DO - 10.3390/jcm11113205

M3 - Journal article

C2 - 35683592

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 11

M1 - 3205

ER -

ID: 78746006